Literature DB >> 10480805

Zanamivir for influenza: a public health perspective. Its use will require careful management by GPs.

J S Nguyen-Van-Tam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10480805      PMCID： PMC1116528          DOI： 10.1136/bmj.319.7211.655

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

2.  Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: results of serum testing and questionnaire.

Authors:  A G Elder; B O'Donnell; E A McCruden; I S Symington; W F Carman
Journal:  BMJ       Date:  1996-11-16

3.  Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

Authors:  F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

4.  The impact of three influenza epidemics on primary care in England and Wales.

Authors:  D M Fleming
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

5.  Rational design of potent sialidase-based inhibitors of influenza virus replication.

Authors:  M von Itzstein; W Y Wu; G B Kok; M S Pegg; J C Dyason; B Jin; T Van Phan; M L Smythe; H F White; S W Oliver
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

6.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.

Authors:  J M Woods; R C Bethell; J A Coates; N Healy; S A Hiscox; B A Pearson; D M Ryan; J Ticehurst; J Tilling; S M Walcott
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

Authors:  M Schilling; L Povinelli; P Krause; M Gravenstein; A Ambrozaitis; H H Jones; P Drinka; P Shult; D Powers; S Gravenstein
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

8.  Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.

Authors:  F G Hayden; J J Treanor; R F Betts; M Lobo; J D Esinhart; E K Hussey
Journal:  JAMA       Date:  1996 Jan 24-31       Impact factor: 56.272
  8 in total
  3 in total

Review 1.  Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.

Authors:  Charles R Beck; Rachel Sokal; Nachiappan Arunachalam; Richard Puleston; Anna Cichowska; Anthony Kessel; Maria Zambon; Jonathan S Nguyen-Van-Tam
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

2.  Response to influenza immunisation during treatment for cancer.

Authors:  J C Chisholm; T Devine; A Charlett; C R Pinkerton; M Zambon
Journal:  Arch Dis Child       Date:  2001-06       Impact factor: 3.791

Review 3.  Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Authors:  Carl J Heneghan; Igho Onakpoya; Matthew Thompson; Elizabeth A Spencer; Mark Jones; Tom Jefferson
Journal:  BMJ       Date:  2014-04-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.